Elevated brain natriuretic peptide is associated with abnormal heart geometry in children with chronic kidney disease

Kidney and Blood Pressure Research

Volumn 33, Issue 2, 2010, Pages 87-93

  Hedvig, J ^a   Podracka L ^a,c   Potoekova D ^b  

^a Department of Pediatrics Medical Faculty UPJS and DFN   (Slovakia)

^b P J AFÁRIK UNIVERSITY   (Slovakia)

^c Med Faculty of Safarik University   (Slovakia)

Author keywords

Brain natriuretic peptide; Cardiac geometry; Chronic kidney disease; Left ventricular hypertrophy

Indexed keywords

BONE MORPHOGENETIC PROTEIN; C REACTIVE PROTEIN; LIPID; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE;

ADOLESCENT; ANEMIA; ARTICLE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONCENTRIC LEFT VENTRICLE HYPERTROPHY; CONTROLLED STUDY; ECCENTRIC LEFT VENTRICLE HYPERTROPHY; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS PATIENT; HUMAN; HYPERPARATHYROIDISM; HYPERTENSION; KIDNEY TRANSPLANTATION; LIPID BLOOD LEVEL; MALE; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; PROGNOSIS; BLOOD; CARDIOMEGALY; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; CHILD; CHRONIC DISEASE; COMPLICATION; ECHOGRAPHY; KIDNEY DISEASE; PREDICTIVE VALUE; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; BIOLOGICAL MARKERS; CARDIOMEGALY; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHILD; CHRONIC DISEASE; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY DISEASES; MALE; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; RISK FACTORS; YOUNG ADULT;

EID: 77949472478     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000295895     Document Type: Article

References (19)

1. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32(suppl 3):S112-S119.
2. Chavers BM, Li S, Collins AJ, Herzog CA: Cardiovascular disease in pediatric chronic dialysis patients. Kidney Int 2002; 62: 648-653.
3. Parfrey PS, Foley RN: The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999; 10: 1606-1615.
4. Mitsnefes MM, Daniels SR, Schwartz SM, Meyer RA, Khoury P, Strife CF: Severe left ventricular hypertrophy in pediatric dialysis: prevalence and predictors. Pediatr Nephrol 2000; 14: 898-902.
5. Longenecker JC, Coresh J, Power NR, Levey AS, Fink NE, Martin A, Klag MJ: Traditional cardiovascular risk factors in dialysis patients compared with general population: The CHOICE study. J Am Soc Nephrol 2002; 13: 1918-1927.
6. Gruppen, MP, Groothoff, JW, Prins, M, van der Wouw P, Offringa M, Bos WJ, Davin JC, Heymans HS: Cardiac disease in young adults patients with end-stage renal disease since childhood: a Dutch cohort study. Kidney Int 2003; 63: 1058-1065. (Pubitemid 36321793)
7. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents: The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114(suppl):555-576.
8. Daniels SR, Kimball TR, Morrison JA, Khoury P, Meyer RA: Indexing left ventricular mass to account for differences in body size in children and adolescents without cardiovascular disease. Am J Cardiol 1995; 76: 699-701.
9. Urbina EM, Gidding SS, Bao W, Pickoff AS, Berdusis K, Berenson GS: Effect of body size, ponderosity, and blood pressure on left ventricular growth in children and young adults in the Bogalusa Heart Study. Circulation 1995; 91: 2400-2406.
10. de Simone G, Kizer J, Chinali M, Roman MJ, Bella JN, Best LG, Lee ET, Devereux RB: Normalization for body size and population-attributable risk of left ventricular hypertrophy: the Strong Heart Study. Am J Hypertens 2005; 18: 191-196. (Pubitemid 40332548)
11. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP: Prognostic implications of echocardiographically determined left ventricular mass in Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.
12. Matteucci MC, Wühl E, Picca S, Mastrostefano A, Rinelli G, Romano C, Rizzoni G, Mehls O, de Simone G, Schaefer F, ESCAPE Trial Group: Left ventricular geometry in children with mild to moderate chronic renal insufficiency. J Am Soc Nephrol 2006; 17: 218-226.
13. Mitsnefes MM, Kimball TR, Border WL, Witt SA, Glascock BJ, Khoury PR, Daniels SR: Impaired left ventricular diastolic function in children with chronic renal failure. Kidney Int 2004; 65: 1461-1466.
14. Grossman W, Jones D, McLaurin LP: Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 1975; 56: 56-64.
15. Cataliotti A, Malatino L, Jougasaki M, Zocalli C, Castellino P, Glacone G, Bellanuova I, Tripepi R, Seminara G, Parlongo S, Stancanelli B, Bonanno G, Fatuzzo P, Rapisarda F, Belluardo P, Signorelli SS, Heublein DM, Lainchburry JG, Leskinen HK, Bailey KR, Redfield MM, Burnett JC Jr: Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc 2001; 76: 1111-1119.
16. Clerico A, Capriolo R, Del Ry S, Gianessi D: Clinical relevance of cardiac natriuretic peptides measured by means of competitive and non-competitive immunoassay methods in patients with renal failure on chronic hemodialysis. J Endocrinol Invest 2001; 24: 24-30.
17. Zoccali C, Mallamaci F, Benedetto FA, Tripepi G, Parlongo S, Cataliotti A, Cutrupi S, Giacone G, Bellanuova I, Cottini E, Malatino LS; Creed Investigators: Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 2001; 12: 1508-1515.
18. Sillberg JS, Barre PE, Prichard SS, Sniderman AD: Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989; 36: 286-290.
19. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM: Arterial calcifications, arterial stiffness, and cardiovascular risk in endstage renal disease. Hypertension 2001; 38: 938-942.